Disorders due to use of alcohol ICD11 code: 6C40
Oral > Solid > tablet: 333 mg
EML status history
Adolescents and adults
The recommendation is for this specific medicine
Patents have expired in most jurisdictions
Read more about patents.
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the inclusion of acamprosate and naltrexone on the core list of the EML for the treatment of alcohol use disorder in adults. The Committee considered that the available evidence showed these medicines to be associated with moderate improvements in abstinence rates, that would translate to meaningful impact at the population level. Both medicines are generally well tolerated and are recommended in WHO guidelines. The Committee considered that the availability of different medicines for alcohol use disorder would provide valuable options and choice for patients and clinicians, and could facilitate increased market competition, reduce costs and improve affordable access for national health systems.